CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Pirtobrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06258174
NCT06258174Phase 1Completed
CompareCT.gov

A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Compare the PK of Pirtobrutinib (LOXO-305) Tablets

Eli Lilly and Company·interventional·Posted Feb 14, 2024·Updated Jan 13, 2025

In Brief

A Phase 1 clinical trial evaluating Pirtobrutinib for Healthy. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedFeb 14, 2024
Enrollment StartSep 28, 2021
Primary CompletionDec 22, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.4 years ago

Interventions

Pirtobrutinibdrug

Administered orally.